## **RESEARCH ARTICLE**

## **Open Access**



# The association between osteoporosis and frailty: a cross-sectional observational study and mendelian randomization analysis

Zhiqiang Que<sup>1†</sup>, Yilong Lin<sup>2†</sup>, Dingqiang Chen<sup>1,3†</sup>, Keyi Xiao<sup>1,3</sup>, Wenbin Xu<sup>1</sup>, Naikun Sun<sup>1,3\*</sup>, Qingmo Yang<sup>2,3\*</sup> and Gang Rui<sup>1,3\*</sup>

## Abstract

**Background** Osteoporosis and frailty are two common features in the elderly population. Despite many review articles mentioning the association between osteoporosis and frailty, there is a lack of original research directly investigating their relationship. Therefore, this study was conducted to examine the correlation between osteoporosis and frailty.

**Methods** We conducted a cross-sectional study using data from the National Health and Nutrition Examination Survey (NHANES), using logistic regression analysis to assess the association of osteoporosis with the frailty index. In addition, we further explored the causal relationship between them using Mendelian randomization (MR) study.

**Results** In the cross-sectional study, 19,091 non-frailty participants and 5878 frailty participants were included in this study. We observed a significant positive association between osteoporosis and frailty after adjusting for demographic characteristics, body mass index (BMI), smoking, and alcohol use (OR=1.454, 95% CI [1.142,1.851], P=0.003). Moreover, the MR study showed a bidirectional causal relationship between osteoporosis and frailty. When osteoporosis was used as an exposure factor, the frailty pooled OR value calculated utilizing the inverse variance weighted (IVW) method was 2.81 (95% CI [1.69, 4.68], P=6.82×10<sup>-5</sup>). When frailty was used as an exposure factor, the OR value calculated using the IVW method was 1.01 (95% CI [1.00,1.01], P=3.65×10<sup>-7</sup>).

**Conclusions** Osteoporosis was positively correlated with frailty, and the results remained robust after adjusting for covariates. Further, MR studies have shown a bidirectional causal relationship between osteoporosis and frailty. **Keywords** Osteoporosis, Frailty, National Health and Nutrition Examination Survey, Mendelian randomization

<sup>†</sup>Zhiqiang Que, Yilong Lin and Dingqiang Chen contributed equally to this work.

\*Correspondence: Naikun Sun sunwenze6@163.com Qingmo Yang yqm8383@163.com



<sup>1</sup>Department of Orthopedics, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China <sup>2</sup>Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China <sup>3</sup>The School of Clinical Medicine, Fujian Medical University, Fuzhou, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

#### Introduction

Osteoporosis is a progressive systemic bone disease characterized by low bone mass, deterioration of bone tissue micro-structure, and increased bone fragility [1]. It is diagnosed using the T-score calculated from bone mineral density (BMD), where osteoporosis is confirmed when the BMD is less than or equal to 2.5 standard deviations (SD) (T-score  $\leq$  -2.5) compared to normal young adults [2]. A variety of factors are closely related to osteoporosis, including age, sex, ethnicity, BMI, smoking, alcohol consumption, diabetes, hyperthyroidism, premature menopause (<45 years), and glucocorticoid use [3, 4]. Approximately 200 million women globally are afflicted by osteoporosis, with osteoporotic fractures affecting 30% of women and 20% of men aged 50 and above [5-7]. As the global population ages, the number of incident osteoporosis-related fractures is expected to increase by 310% in 2050 or earlier [8]. The resulting economic burden is also significant, spending about \$17.9 billion in the US and £4 billion in the UK per year, respectively [9–11]. Therefore, the early identification and treatment of osteoporosis is important.

Frailty is a state in which individuals face a higher risk of negative outcomes due to the decline in physiological reserves and functioning of multiple organ systems associated with aging [12]. Research indicates that 25%-50%of individuals aged 85 and above experience frailty [13, 14]. It cannot be overlooked due to its association with increased healthcare utilization, disability, and mortality among individuals in frail states [15]. The high prevalence of frailty and its substantial social burden underscore the significance of addressing this issue. While numerous review articles have highlighted the connection between frailty and osteoporosis, the direct investigation of their relationship is limited in original studies, leading to conflicting findings across various research studies [16, 17]. Therefore, the current understanding of the relationship between osteoporosis and frailty is insufficient and this topic is still worth exploring.

National Health and Nutrition Examination Survey (NHANES) is a program to evaluate the health and nutritional status of both adults and children in the US [18]. It combines interviews and physical examinations to collect data, providing a vast array of reliable information for determining the prevalence of major diseases and risk factors for diseases. Mendelian randomization (MR) analysis is an epidemiological method that utilizes genetic variations as instrumental variables (IVs) to evaluate the causal association between exposure factors and outcome events. MR analysis offers a distinct advantage in establishing an unbiased causal relationship between exposure and outcomes.

Hence, we undertook a cross-sectional study to explore the association between osteoporosis and frailty using the NHANES data (2005–2010, 2013–2014, 2017–2018). The MR analysis was used to investigate the bidirectional causal effect of osteoporosis on frailty. The goal of this study is to provide reliable epidemiological evidence on the relationship between osteoporosis and frailty, raise awareness of the early recognition of these two conditions in clinical practice, and even accelerate the discovery of effective strategies to prevent osteoporosis and frailty.

#### Methods

## The cross-sectional analysis *Data source*

Data for this cross-sectional study are from NHANES (2005–2010, 2013–2014, 2017–2018). The survey collects demographic information, dietary habits, examination results, laboratory data, and questionnaire responses annually from a nationally representative sample of around 5000 individuals and publishes the results biennially. The study protocol received approval from the Ethics Review Board of the National Center for Health Statistics. All participants provided written informed consent. This study followed the Reporting on Strengthening Observational Studies in Epidemiology (STROBE) reporting guidelines.

#### Ascertainment of osteoporosis

Dual-energy x-ray absorptiometry (DXA) scans of the proximal femur have been performed at the NHANES mobile examination center (MEC) since 2005. However, femoral BMD assessments were not performed during the 2011–2012 and 2015–2016 cycles. Therefore, data from five NHANES cycles were utilized in this study: 2005–2010, 2013–2014, and 2017–2018. According to the diagnostic criteria of the WHO [2], osteoporosis is defined as a BMD value equal to or less than 2.5 SD compared to a normal young population. This criterion was applied to the femoral neck and lumbar region to diagnose osteoporosis.

#### Ascertainment of frailty

According to previous research [19], frailty index (FI) is computed by dividing the accumulated deficits of a participant by the overall number of items assessed. When the FI>0.21, the individual is defined as frailty. The evaluation indicators involved 7 aspects: **cognition** (experience confusion/memory problems), **dependence** (managing money difficulty; stooping, crouching, kneeling difficulty; lifting or carrying difficulty; house chore difficulty; preparing meals difficulty; standing up from armless chair difficulty; getting in and out of bed difficulty; using fork, knife, drinking from cup difficulty; dressing yourself difficulty; standing for long periods difficulty; grasp/holding small objects difficulty; attending

social event difficulty; push or pull large objects difficulty; walking for a quarter mile difficulty; walking up 10 steps difficulty), depressive symptoms (have little interest in doing things; feeling down, depressed, or hopeless; trouble sleeping or sleeping too much; feeling tired or having little energy; poor appetite or overeating; feeling bad about yourself; trouble concentrating on things), comorbidities (arthritis; thyroid problems; chronic bronchitis; cancer; congestive heart failure; coronary heart disease; angina; heart attack; stroke; blood pressure; diabetes; weak/failing kidneys; urinary leakage), hospital utilization and access to care (self-rated health; health now compared with 1 year ago; overnight hospital patient in past year; frequency of health care use during past year; number of prescribed medications), physical performance and anthropometry (body mass index; handgrip strength), and laboratory values(glycohemoglobin (%); red blood cell count (million cells/mL); hemoglobin (g/ dL); red cell distribution width (%); lymphocyte percent (%); segmented neutrophils percent (%)), with a total of 49 indicators. Detailed grading criteria have been shown in Supplementary Table 1.

#### Covariates

Drawing upon previous literature, and clinical expertise, and considering the NHANES database accessibility, we incorporated the subsequent indicators as covariates, including age, ethnicity, educational level, marital status, poverty income ratio (PIR), BMI, smoking, and alcohol consumption. Ethnicity was categorized into non-Hispanic White, non-Hispanic Black, Mexican American, and other. The educational level was segmented into under high school, high school or equivalent, and above high school. Depending on whether the individual is living with a partner, dividing the marital status into married or living with partner and other. The other group includes the population who never married, divorced, separated, and widowed. PIR was classified as 0-1.3 PIR, >1.3-3.5 PIR, >3.5 PIR. BMI was divided into four levels, including underweight ( $< 18.5 \text{ kg/m}^2$ ), normal (18.5– 24.9 kg/m<sup>2</sup>), overweight (25–29.9 kg/m<sup>2</sup>), obese ( $\geq$  30 kg/ m<sup>2</sup>). Smoking was divided into three groups, including never smoking, former smoking and now smoking; Alcohol consumption was divided into five groups based on whether and to what extent alcohol is consumed, including never, former, mild, moderate, and heavy; Individuals with diabetes and taking diabetes drugs would be regarded as diabetic patients. Participants who actively respond to the questionnaire with hypertension and who are taking medication for hypertension would be considered hypertensive patients.

#### Statistical analysis

In this study, continuous variables were expressed as mean and SD, and categorical variables were presented as numbers (n) and percentages (%). The population was categorized into the non-frailty group (N=19,091)and frailty group (N=5878) based on FI, and the T-test and Chi-square test were employed to assess significant differences between these groups. Logistic regression models were used to evaluate the correlation between osteoporosis and frailty. In this analysis, we built four models. The crude model did not include adjustments for any covariates. Model 1 was adjusted for age, sex, ethnicity, marital status, PIR, and education level. Model 2 was adjusted for age, sex, ethnicity, marital status, PIR, education level, and BMI. Model 3 was adjusted for age, sex, ethnicity, marital status, PIR, education level, BMI, smoking and alcohol use. Further stratification analyses were performed for age, ethnicity, PIR, marital status, education level, smoking status, drinking, and BMI. All statistical analyses were conducted using R software (version 4.3.2), and significance was determined at a threshold of *p* < 0.05.

#### Mendelian randomization analysis Genome-wide association studies sources

The summary data of osteoporosis for this analysis were obtained from Genome-Wide Association Studies (GWAS) (ID: ebi-a-GCST90038656) [20], comprising 7751 cases and 476,847 controls, all participants were European population. The data of FI (ID: ebi-a-GCST90020053) were sourced from the UK Biobank (n=164,610) and Swedish TwinGene participants (n=10,616)'s GWAS meta-analysis. 175,226 participants of European descent were obtained and a total of 49 items were assessed, with a mean defect ratio of 0.129 (0.075) [21]. A total of 10,616 individuals were obtained from TwinGene, all of European ancestry. A total of 44 items were evaluated, with an average defect ratio of 0.121 (0.080).

#### Selection of genetic instrumental variables

Three assumptions [22] are met in this MR study: (1) The link between gene expression and IVs is considerable; (2) IVs are not associated with confounders; and (3) IVs only affect outcomes through exposure. For this MR analysis, first, single nucleotide polymorphisms (SNPs) strongly correlated with exposure were selected as IVs ( $P < 5.0 \times 10^{-5}$ ). Second, we excluded SNPs with linkage disequilibrium (LD) ( $r^2 > 0.001$ , kb=10,000). Next, the IVs related to outcome and F-statistics<10 were excluded in this study. Through Steiger's test, SNPs that exhibited a lack of directional consistency were identified and removed from the analysis. At last, the MR-presso method was used to find and filter the outlier IVs.

#### Statistical analysis

This MR analysis was conducted in R software (version 4.3.2) using "TwoSampleMR package" [23], "Mendelian Randomization package" [24], and "MR-PRESSO package" [25]. The inverse variance weighted (IVW) method was used as the primary analytical approach. While the IVW method offers precise estimates, it is vulnerable to pleiotropic IVs. [26]. The biggest difference between the MR Egger method and the IVW method is that the intercept term is considered in the regression, which enables the assessment of the presence of horizontal pleiotropy [27]. The weighted median (WM) method is reliable when the majority of weights (>50%) in the analvsis are derived from valid instrumental variables [28]. MR-presso method can exclude possible abnormal values, provide new adjusted results, and correct horizontal pleiotropy. Therefore, we complement the MR Egger, Weighted median, and MR Egger methods. Sensitivity analyses were performed utilizing Cochran's Q test [29], MR-Egger intercept test, Steiger's test, leave-one-out test, and funnel plot.

#### Result

#### **Baseline characteristics of study participants**

In the five cycles of 2005-2010, 2013-2014, and 2017-2018, a total of 50,463 participants were included, 25,494 individuals with missing BMD data were excluded, 0 participants with missing frailty index scores were excluded, and 0 individuals with missing weight information or weighted 0 were excluded, and finally 24,969 participants, including 19,091 non-frailty participants and 5878 frailty participants, were included in the study (Fig. 1). Table 1 presents the weighted characteristics of the populations included in this study. The prevalence of frailty is relatively high in females and non-Hispanic blacks. Married or living with a partner has a lower prevalence of frailty than others. Individuals with frailty have lower income, higher age and BMI than those without frailty, and have shown a correlation with education level, alcohol consumption and smoking.

#### Association between osteoporosis and frailty

The results of this cross-sectional study using NHANES data are shown in Table 2. The incidence of osteoporosis



Fig. 1 Flow chart of selecting eligible participants

### Table 1 Demographic and clinical characteristics of the study participants in the NHANES

Variable	Total (N=24,969)	non-Frailty ( <i>N</i> = 19,091)	Frailty ( <i>N</i> = 5878)	<i>P</i> value
Age	44.91(0.31)	44.05(0.32)	48.74(0.47)	< 0.0001
PIR	3.06(0.04)	3.20(0.04)	2.45(0.05)	< 0.0001
Sex				< 0.0001
Female	12,118(49.85)	9137(48.70)	2981(54.97)	
Male	12,851(50.15)	9954(51.30)	2897(45.03)	
Ethnicity				< 0.0001
Non-Hispanic White	10,598(69.11)	8337(70.40)	2261(63.38)	
Non-Hispanic Black	5372(10.77)	3690( 9.47)	1682(16.57)	
Mexican American	4974(8.51)	3957(8.68)	1017(7.75)	
Other	4025(11.61)	3107(11.46)	918(12.29)	
Marital status				< 0.0001
Married or living with partner	11,571(56.20)	9491(66.07)	2080(55.09)	
Other	8492(31.30)	6331(33.93)	2161(44.91)	
Education level				< 0.0001
Under high school	5628(13.04)	3704(10.98)	1924(22.30)	
High school or equivalent	9754(36.18)	7340(34.86)	2414(42.19)	
Above high school	9562(50.70)	8029(54.16)	1533(35.51)	
Alcohol use				< 0.0001
Never	2285( 8.28)	1741(10.10)	544(12.46)	
Former	3026(11.45)	2082(12.60)	944(24.34)	
Mild	5918(29.86)	4848(38.52)	1070(33.89)	
Moderate	2552(13.43)	2145(17.56)	407(14.01)	
Heavy	3333(16.02)	2823(21.22)	510(15.30)	
Smoke				< 0.0001
Never	9824(45.16)	8148(55.46)	1676(41.35)	
Former	4909(22.17)	3657(24.97)	1252(31.49)	
Now	3945(17.73)	2920(19.57)	1025(27.16)	
Hypertension				< 0.0001
No	16,329(65.50)	13,398(70.43)	2931(43.99)	
Yes	8567(34.36)	5640(29.57)	2927(56.01)	
Diabetes				< 0.0001
No	22,320(91.25)	17,841(94.61)	4479(76.30)	
Yes	2649(8.75)	1250( 5.39)	1399(23.70)	
Osteoporosis				< 0.0001
No	23,117(93.96)	17,923(95.15)	5194(88.66)	
Yes	1852( 6.04)	1168(4.85)	684(11.34)	
BMI	27.25(0.08)	27.09(0.08)	27.99(0.14)	< 0.0001

Continuous variables were presented by mean and standard deviation (SD), and categorical variables were presented with numbers(n) and percentages (%) PIR, ratio of family income to poverty; BMI, body mass index

Table 2 Multivariate	logistic red	pression anal	vsis of osteo	porosis with frailty
			/	

Character	acter Crude model		Model 1		Model 2		Model 3	
	95%Cl	Р	95%CI	Р	95%CI	Р	95%CI	Р
non-Frailty	ref		ref		ref		ref	
Frailty	2.509(2.183,2.883)	< 0.0001	1.359(1.094,1.690)	0.006	1.654(1.328,2.061)	< 0.0001	1.454(1.142,1.851)	0.003

Crudel model: no adjustment was made for any covariates

Model 1:adjusting for age, sex, ethnicity, marital status, PIR, education level

Model 2:adjusting for age, sex, ethnicity, marital status, PIR, education level, BMI

Model 3:adjusting for age, sex, ethnicity, marital status, PIR, education level, BMI, smoking, alcohol use

Character	95% CI	Р	P for in-
			teraction
Sex			< 0.0001
Female	2.008(1.682,2.397)	< 0.0001	
Male	3.326(2.757,4.013)	< 0.0001	
Ethnicity			0.28
Non-Hispanic White	2.780(2.311,3.342)	< 0.0001	
Non-Hispanic Black	2.586(1.999,3.346)	< 0.0001	
Mexican American	2.153(1.796,2.581)	< 0.0001	
Other	2.267(1.590,3.233)	< 0.0001	
Marital status			0.117
Married or living with partner	2.160(1.717,2.717)	< 0.0001	
Other	2.801(2.138,3.669)	< 0.0001	
PIR			< 0.001
0-1.3 RIP	1.537(1.262,1.872)	< 0.0001	
>1.3-3.5 RIP	2.450(2.000,3.001)	< 0.0001	
>3.5 RIP	3.431(2.467,4.772)	< 0.0001	
Education level			0.002
Under high school	1.460(1.195,1.784)	< 0.001	
High school or	2.052(1.654,2.547)	< 0.0001	
equivalent			
Above high school	2.983(2.091,4.255)	< 0.0001	
Alcohol use			0.22
Never	2.126(1.464,3.086)	< 0.001	
Former	1.860(1.205,2.873)	0.006	
Mild	2.004(1.423,2.821)	< 0.001	
Moderate	2.658(1.329,5.318)	0.006	
Heavy	4.234(2.379,7.533)	< 0.0001	
Smoke			0.34
Never	2.978(2.298,3.858)	< 0.0001	
Former	2.302(1.724,3.072)	< 0.0001	
Now	2.387(1.652,3.450)	< 0.0001	
BMI			0.018
Underweight	1.570(1.158,2.128)	0.004	
Normal	3.014(2.369,3.835)	< 0.0001	
Overweight	2.586(2.021,3.307)	< 0.0001	
Obese	2,148(1,372,3,362)	0.001	

 Table 3
 Stratified associations between osteoporosis and frailty according to baseline characteristics

The non-frailty group was used as a reference

PIR, ratio of family income to poverty; BMI, body mass index

showed a significantly positive correlation with frailty. The OR values of crude model, model 1, model 2 and

model 3 were 2.509(95% CI [2.183,2.883], P < 0.0001), 1.359(95% CI [1.094,1.690], P = 0.006), 1.654(95% CI [1.328, 2.061], P < 0.0001) and 1.454(95% CI [1.142, 1.851], P = 0.003), respectively. In addition, stratified analyses were conducted, revealing a consistent association between osteoporosis and frailty across various strata, including ethnicity, marital status, alcohol use and smoking status. (Table 3).

#### The causal association between osteoporosis and frailty

A comprehensive bidirectional two-sample MR analysis was used to investigate the causal relationship between osteoporosis and frailty (Fig. 2). We identified a significant causal association between osteoporosis and frailty. The pooled odds ratio (OR) obtained through the IVW method was 2.81 (95% CI [1.69,4.68],  $P=6.82\times10^{-5}$ ) for per SD increase in the prevalence of osteoporosis. Similar results were obtained using the MR Egger (OR=4.24, 95% CI [1.07,16.87], P=4.21×10<sup>-2</sup>), Weighted median  $(OR=2.55, 95\% CI [1.28, 5.09], P=7.72 \times 10^{-3})$ , and MRpresso (OR=2.81, 95% CI [1.69,4.68],  $P=1.11\times10^{-4}$ ). To explore whether the causal impact of osteoporosis on frailty is influenced by other confounding factors, we performed a multivariate MR analysis. After adjusting for these factors, including BMI, blood pressure, heart failure, coronary heart disease, stroke, and type 2 diabetes, the results remained statistically significant. (Fig. 3). In reverse Mendelian randomization, although the results from the MR analysis remain significant, the absolute value of the beta coefficient is relatively small. The osteoporosis pooled OR value calculated using the IVW method was 1.01 (95% CI [1.00,1.01],  $P=3.65\times10^{-7}$ ) for per SD increasing the prevalence of frailty. Both MR Egger (OR = 1.01, 95% CI [1.00, 1.01],  $P = 4.25 \times 10^{-2}$ ) and MR-presso (OR = 1.01, 95% CI [1.00, 1.01],  $P = 7.18 \times 10^{-7}$ ) also demonstrated significant causal associations (Fig. 2).

#### Sensitivity analysis

To assess horizontal pleiotropy, we utilized Cochran's Q test, MR-Egger intercept test, leave-one-out analyses, and funnel plot. The p-values from MR-Egger intercept tests, chosen by IVW, suggested the absence of horizon-tal pleiotropy as they exceeded 0.05. For the causal effect

Exposure	Outcome	Method	Beta(95%CI)		OR(95%CI)		Р
Osteoporosis	Frailty index	Inverse variance weighted	1.03(0.53 to 1.54)		2.81(1.69 to 4.68)	· · · · · · · · · · · · · · · · · · ·	6.82e-05
Osteoporosis	Frailty index	MR Egger	1.44(0.06 to 2.83)	ı <b></b>	4.24(1.07 to 16.87)		→4.21e-02
Osteoporosis	Frailty index	Weighted median	0.94(0.25 to 1.63)		2.55(1.28 to 5.09)		7.72e-03
Osteoporosis	Frailty index	MR Presso	1.03(0.53 to 1.54)		2.81(1.69 to 4.68)	·	1.11e-04
Frailty index	Osteoporosis	Inverse variance weighted	0.01(0.00 to 0.01)	•	1.01(1.00 to 1.01)	•	3.65e-07
Frailty index	Osteoporosis	MR Egger	0.01(0.00 to 0.01)	•	1.01(1.00 to 1.01)	•	4.25e-02
Frailty index	Osteoporosis	Weighted median	0.00(-0.01 to 0.02)	•	1.00(0.99 to 1.02)	•	3.58e-01
Frailty index	Osteoporosis	MR Presso	0.01(0.00 to 0.01)	•	1.01(1.00 to 1.01)	<b>•</b>	7.18e-07
			-1	0	3 (	) 1	6

Fig. 2 Associations between osteoporosis and frailty in two sample MR analyses

Adjustment	nsnp	Beta(95%CI)		Р
Body mass index	13	1.31(0.38 to 2.24)	• • • • • • • • • • • • • • • • • • •	5.85e-03
Systolic blood pressure	6	1.80(0.89 to 2.72)	<b>⊢</b> −−−1	1.12e-04
Diastolic Blood Pressure	5	1.59(0.70 to 2.49)	<b></b>	5.08e-04
Hypertension	14	0.91(0.22 to 1.61)		9.58e-03
Heart failure	18	1.07(0.48 to 1.67)		3.96e-04
Coronary heart disease	17	1.28(0.65 to 1.91)		6.46e-05
Stroke	18	1.17(0.54 to 1.80)	<b></b>	2.83e-04
Type 2 diabetes	8	2.15(1.12 to 3.18)	<b>⊢</b>	4.28e-05
		-2	0 :	☐ 3.5

Fig. 3 MR study of the relationship between osteoporosis and frailty after adjusting for confounders

of osteoporosis on frailty, the Cochrane Q test indicated the presence of heterogeneity (Cochran's Q-derived *P*-value=0.04), therefore, we employed the IVW random-effects model. In contrast, there was no heterogeneity present for reverse causality. Supplementary Figure S1–S8 display scatter plots, forest plots, leave-one-out plots, and funnel plots, indicating that the estimates remained unaffected by individual SNPs and there were no violations of assumptions.

#### Discussion

In this study, we conducted a cross-sectional study utilizing NHANES data to explore the association between osteoporosis and frailty. The findings of this cross-sectional study revealed a positive correlation between the incidence of osteoporosis and frailty, and that the results remained robust after adjusting for covariates and performing stratified analyses. In addition, we further explored the causal association between osteoporosis and frailty through MR study and found that there is a bidirectional causal relationship between them. To the best of our knowledge, this study represents the first investigation into the association between osteoporosis and frailty utilizing the NHANES database and MR analysis.

Although many review articles have spoken about the association between osteoporosis and frailty, few original studies directly investigate the relationship between them, and even the results of these studies are inconsistent [30–34]. A previous cohort study involving 405 participants concluded that the association between osteoporosis alone and frailty was weak and that the likelihood of frailty was only higher when sarcopenia and osteoporosis coexisted [35]. The same findings were evident in another cross-sectional study that included 250 participants [32], indicating that the association between severe osteopenia/osteoporosis and frailty in

older women in the community did not reach statistical significance. However, when sarcopenia and severe osteopenia/osteoporosis coexisted, the association significantly strengthened. The participants in both studies were from the community, which may introduce cohort bias. Additionally, the relatively small sample size could impact the interpretation of the findings. Nevertheless, some studies provide evidence for a notable association between osteoporosis and frailty. Liu et al. [36] discovered an association between frailty and lower BMD, even after controlling for age, sex, and functional status. In addition, another cross-sectional study of postmenopausal women similarly showed that older adults with osteoporosis were at greater risk of frailty syndrome, with more than 75% accuracy in predicting frailty using osteoporosis [30]. However, there were some differences in the definition of frailty between these studies and ours, using Fried's standard definition, which included exhaustion, weakness, slowness, physical inactivity, and weight loss. In this study, we defined frailty using FI, assessing 49 items involving seven aspects, including cognition, dependence, depressive symptoms, comorbidities, hospital utilization and access to care, physical performance and anthropometry, and laboratory values, which were defined as frailty when FI>0.21. The criteria for defining frailty have an impact on the results of association [37]. Furthermore, all these studies were limited to cross-sectional designs and did not explore the causal relationship between osteoporosis and frailty further.

Our results from the cross-sectional study are in line with the MR study, indicating a significant correlation between osteoporosis and frailty. Both osteoporosis and frailty are age-related diseases, accompanied by other common features relating to age, such as muscle loss, weight loss, physical activity, falls, cognitive decline, etc., which may also strengthen the relationship between the two to some extent [29]. Some fundamental research have suggested the presence of shared pathophysiological mechanisms between osteoporosis and frailty, such as endocrine disruption and increased pro-inflammatory factors [38]. Hormones such as testosterone, estrogen, growth hormone, insulin-like growth factor 1 (IGF-1), vitamin D, and cytokines fluctuate similarly in populations with osteoporosis and frailty [38]. Estrogen and IGF-1 decrease with age, mediating the activation of osteoclast cytokines, subsequently promoting bone resorption, ultimately leading to osteoporosis [39], and by mediating elevated catabolic cytokine levels, promoting decreased muscle mass and strength, ultimately leading to frailty [40]. This elucidates why the association between osteoporosis and frailty is more significant under conditions of advanced age and sarcopenia. Chronic inflammation is one of the key factors that lead to frailty [12], similarly, the process of bone loss is inseparable from inflammation [41]. Estrogen and androgens are important inhibitors of interleukin-6 (IL-6) gene expression [42]. As the withdrawal of these sex hormones occurs, the amount of IL-6 gradually increases, and it promotes bone loss by enhancing osteoclast activity. A study has shown that the inflammatory marker C-reactive protein is also associated with frailty and osteoporosis [40]. In addition, osteoprotein, a powerful marker of osteoclast activity, was significantly elevated in patients with both osteoporosis and frailty [43, 44]. The common pathophysiological process provides a reasonable explanation for the two-way causal relationship between osteoporosis and frailty.

Some of the advantages of our research are as follows. First, the data for the cross-sectional study were obtained from the NHANES database, and we integrated samples from five cycles to obtain a large sample that was broadly representative. Second, we adjusted for covariates including demographic characteristics, BMI, smoking, and alcohol use, and performed stratified analysis to make the results more reliable. Finally, we further explored the causal relationship between osteoporosis and frailty by employing MR analyses. Still, there are some shortcomings to this study. First, most of the NHANES data we used are from questionnaires based on participants' memory, and there will inevitably be some recall bias. Second, the absence of demographic data on osteoporosis in the MR study precluded us from conducting a subgroup analysis. Finally, additional basic experimental validations are necessary to affirm the association between osteoporosis and frailty, consequently enabling the prediction of future frailty risk based on the presence of osteoporosis.

#### Conclusions

This study revealed a positive correlation between osteoporosis and frailty, with the findings remaining robust even after adjusting for various covariates. An additional MR analysis revealed a bidirectional causal relationship between osteoporosis and frailty. The current study offers a solid foundation for the concurrent management of osteoporosis and frailty. Nonetheless, further research is essential to delve deeper into the shared pathophysiological mechanisms between these two conditions.

#### Abbreviations

BMD	Bone mineral density
BMI	Body mass index
DXA	Dual-energy x-ray absorptiometry
IGF-1	Insulin-like growth factor 1
IL-6	Interleukin-6
IVs	Instrumental variables
IVW	Inverse variance weighted
GWAS	Genome-wide association studies
LD	Linkage disequilibrium
MEC	Mobile examination center
MR	Mendelian randomization
NHANES	National Health and Nutrition Examination Survey
OR	Odds ratio
PIR	Poverty income ratio
SNPs	Single nucleotide polymorphisms
WHO	World Health Organization
WM	Weighted median

#### **Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13018-024-04875-w.

Supplementary Material 1

Supplementary Material 2

#### Acknowledgements

Thanks to Zhang Jing (Second Department of Infectious Disease, Shanghai Fifth People's Hospital, Fudan University) for his work on the NHANES database. His outstanding work, nhanesR package and webpage, makes it easier for us to explore NHANES database.

#### Author contributions

Conceptualization: ZQ and YL; Methodology: ZQ, YL and DC; Software: ZQ, YL and DC; Validation: KX; Formal analysis: ZQ and YL; Investigation: DC; Resources: WX; Data curation: ZQ and YL; Writing-original draft preparation: ZQ, YL and DC; Writing-review and editing: ZQ, YL and DC; Visualization: KX; Supervision: GR, QY and NS; Project administration: GR, QY and NS; Funding acquisition: GR. All authors reviewed the manuscript.

#### Funding

This research was funded by the Xiamen Science and Technology Plan Project (3502Z20224ZD1003).

#### Data availability

All NHANES data included in this study were publicly available at http:// www.cdc.gov/nchs/nhanes/ and all GWAS data included in MR analysis were publicly available at https://gwas.mrcieu.ac.uk/.

#### Declarations

#### Ethics approval and consent to participate

The study protocol of NHANES received approval from the Ethics Review Board of the National Center for Health Statistics. All participants provided written informed consent. This study followed the Reporting on Strengthening Observational Studies in Epidemiology reporting guidelines.

#### **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare no competing interests.

Received: 27 March 2024 / Accepted: 25 June 2024 Published online: 09 July 2024

#### References

- Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, Harvey N, Kanis J, Leyland S, Low R, McCloskey E, Moss K, Parker J, Paskins Z, Poole K, Reid DM, Stone M, Thomson J, Vine N. Compston J. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022;17(1):58. https://doi.org/10.1007/s11657-022-01061-5.
- Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Min Res. 1994;9(8):1137–41. https://doi.org/10.1002/ jbmr.5650090802.
- Ak A. K I. update on osteoporosis screening and management. Med Clin N Am. 2021;105(6). https://doi.org/10.1016/j.mcna.2021.05.016.
- M S.; C D. osteoporosis in elderly: prevention and treatment. Clin Geriatr Med 2002, 18 (3). https://doi.org/10.1016/s0749-0690(02)00022-8.
- Curtis EM, van der Moon VR, van den Bergh RJ, Geusens JPW, de Vries P, van Staa F, Cooper TP. Harvey N. C. Epidemiology of fractures in the United Kingdom 1988–2012: variation with age, sex, geography, ethnicity and socioeconomic status. Bone. 2016;87:19–26. https://doi.org/10.1016/j. bone.2016.03.006.
- Melton LJ, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Min Res. 1998;13(12):1915–23. https://doi. org/10.1359/jbmr.1998.13.12.1915.
- Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359(9321):1929–36. https://doi.org/10.1016/S0140-6736(02)08761-5.
- Ja BG;OJ. K. World-wide projections for hip fracture. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 1997;7(5). https://doi.org/10.1007/pl00004148.
- Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1):136. https://doi.org/10.1007/ s11657-013-0136-1.
- Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The epidemiology of osteoporosis. Br Med Bull. 2020;133(1):105–17. https://doi. org/10.1093/bmb/ldaa005.
- Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General; Reports of the Surgeon General; Office of the Surgeon General (US): Rockville (MD), 2004.
- Chen X, Mao G, Leng SX. Frailty syndrome: an overview. Clin Interv Aging. 2014;9:433–41. https://doi.org/10.2147/CIA.S45300.
- Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc. 2010;58(4):681–7. https://doi.org/10.1111/j.1532-5415.2010.02764.x.
- Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol Biol Sci Med Sci. 2001;56(3):M146–156. https://doi.org/10.1093/ gerona/56.3.m146.
- Buckinx F, Rolland Y, Reginster J-Y, Ricour C, Petermans J, Bruyère O. Burden of frailty in the elderly population: perspectives for a public health challenge. Arch Public Health. 2015;73(1):19. https://doi.org/10.1186/s13690-015-0068-x.

- Greco EA, Pietschmann P, Migliaccio S. Osteoporosis and Sarcopenia increase Frailty Syndrome in the Elderly. Front Endocrinol (Lausanne). 2019;10:255. https://doi.org/10.3389/fendo.2019.00255.
- Heng MWY, Chan AWD, Man REK, Fenwick EK, Chew STH, Tay L, Sien NY, Ng D, Koh FH, Yong E-L, Gupta P, Lamoureux EL. Individual and combined associations of Sarcopenia, osteoporosis and obesity with frailty in a multiethnic Asian older adult population. BMC Geriatr. 2023;23(1):802. https://doi. org/10.1186/s12877-023-04500-1.
- NHANES National Health and Nutrition Examination Survey Homepage. https://www.cdc.gov/nchs/nhanes/index.htm (accessed 2024-03-18).
- Hakeem FF, Bernabé E, Sabbah W. Association between Oral Health and Frailty among American older adults. J Am Med Dir Assoc. 2021;22(3):559– e5632. https://doi.org/10.1016/j.jamda.2020.07.023.
- Dönertaş HM, Fabian DK, Valenzuela MF, Partridge L, Thornton JM. Common genetic associations between age-related diseases. Nat Aging. 2021;1(4):400– 12. https://doi.org/10.1038/s43587-021-00051-5.
- Atkins JL, Jylhävä J, Pedersen NL, Magnusson PK, Lu Y, Wang Y, Hägg S, Melzer D, Williams DM. Pilling L. C. A genome-wide association study of the frailty index highlights brain pathways in ageing. Aging Cell. 2021;20(9):e13459. https://doi.org/10.1111/acel.13459.
- Emdin CA, Khera AV, Kathiresan S, Mendelian Randomization. JAMA. 2017;318(19):1925–6. https://doi.org/10.1001/jama.2017.17219.
- Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C, Martin RM, Davey Smith G, Gaunt TR, Haycock PC. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408. https://doi.org/10.7554/eLife.34408.
- Cn B Jr, Aj F, Am G, Jr M. S.; S B. MendelianRandomization v0.5.0: updates to an R package for performing Mendelian randomization analyses using summarized data. Wellcome open Res. 2020;5. https://doi.org/10.12688/ wellcomeopenres.16374.2.
- Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–8. https:// doi.org/10.1038/s41588-018-0099-7.
- Mounier N, Kutalik Z. Bias correction for inverse variance weighting mendelian randomization. Genet Epidemiol. 2023;47(4):314–31. https://doi. org/10.1002/gepi.22522.
- Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–25. https://doi.org/10.1093/ije/dyv080.
- Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol. 2016;45(6):1961–74. https://doi.org/10.1093/ije/dyw220.
- Greco MFD, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in mendelian randomisation studies with summary data and a continuous outcome. Stat Med. 2015;34(21):2926–40. https://doi.org/10.1002/sim.6522.
- Rahimipour Anaraki S, Mohammadian A, Saghafian Larijani S, Niksolat M, Rashedi V, Gholizadeh Mesgarha M. Frailty syndrome in women with osteoporosis, should physicians consider screening? A cross-sectional study. Bone Rep. 2023;19:101722. https://doi.org/10.1016/j.bonr.2023.101722.
- Cattaneo F, Buondonno I, Cravero D, Sassi F, D'Amelio P. Musculoskeletal diseases Role in the Frailty Syndrome: a case-control study. Int J Environ Res Public Health. 2022;19(19):11897. https://doi.org/10.3390/ijerph191911897.
- Frisoli A, Chaves PH, Ingham SJM, Fried LP. Severe osteopenia and osteoporosis, Sarcopenia, and frailty status in community-dwelling older women: results from the women's Health and Aging Study (WHAS) II. Bone. 2011;48(4):952–7. https://doi.org/10.1016/j.bone.2010.12.025.
- Calado LB, Ferriolli E, Moriguti JC, Martinez EZ, Lima NK. Da C. Frailty syndrome in an independent urban population in Brazil (FIBRA study): a cross-sectional populational study. Sao Paulo Med J. 2016;134(5):0. https:// doi.org/10.1590/1516-3180.2016.0078180516.
- Tembo MC, Mohebbi M, Holloway-Kew KL, Gaston J, Sui SX, Brennan-Olsen SL, Williams LJ, Kotowicz MA, Pasco JA. The contribution of musculoskeletal factors to physical frailty: a cross-sectional study. BMC Musculoskelet Disord. 2021;22(1):921. https://doi.org/10.1186/s12891-021-04795-4.
- Laskou F, Fuggle NR, Patel HP, Jameson K, Cooper C, Dennison E. Associations of osteoporosis and sarcopenia with frailty and multimorbidity among participants of the Hertfordshire Cohort Study. J Cachexia Sarcopenia Muscle. 2022;13(1):220–9. https://doi.org/10.1002/jcsm.12870.

- Liu L-K, Lee W-J, Chen L-Y, Hwang A-C, Lin M-H, Peng L-N, Chen L-K. Association between Frailty, osteoporosis, Falls and Hip fractures among Community-Dwelling people aged 50 years and older in Taiwan: results from I-Lan Longitudinal Aging Study. PLoS ONE. 2015;10(9):e0136968. https://doi. org/10.1371/journal.pone.0136968.
- Sternberg SA, Levin R, Dkaidek S, Edelman S, Resnick T, Menczel J. Frailty and osteoporosis in older women–a prospective study. Osteoporos Int. 2014;25(2):763–8. https://doi.org/10.1007/s00198-013-2471-x.
- Rolland Y, van Abellan G, Bénétos A, Blain H, Bonnefoy M, Chassagne P, Jeandel C, Laroche M, Nourhashémi F, Orcel P, Piette F, Ribot C, Ritz P, Roux C, Taillandier J, Trémollières F, Weryha G. Vellas B. Frailty, osteoporosis and hip fracture: causes, consequences and therapeutic perspectives. J Nutr Health Aging. 2008;12(5):335–46. https://doi.org/10.1007/BF02982665.
- Am CJ, Ja K;PT, Ga L;GD. Role of endocrine-immune dysregulation in osteoporosis, Sarcopenia, frailty and fracture risk. Mol Aspects Med. 2005;26(3). https://doi.org/10.1016/j.mam.2005.01.004.
- 40. Jd SE. Frailty in older adults: insights and interventions. Cleve Clin J Med. 2005;72(12). https://doi.org/10.3949/ccjm.72.12.1105.
- Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence.

Ann N Y Acad Sci. 2000;908:244–54. https://doi.org/10.1111/j.1749-6632.2000. tb06651.x.

- Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245–70. https://doi. org/10.1146/annurev.med.51.1.245.
- Valentini A, Cianfarani MA, Tarantino U, Di Daniele N, Bertoli A. Osteoprotegerin as a biomarker of geriatric frailty syndrome. Aging. 2019;11(14):4900–9. https://doi.org/10.18632/aging.102083.
- Pandey A, Khan YA, Kushwaha SS, Mohammed F, Verma A. Role of serum Osteoprotegerin as a Diagnostic Indicator of primary osteoporosis in Perimenopausal and Postmenopausal women: an Indian perspective. Malays Orthop J. 2018;12(1):31–5. https://doi.org/10.5704/MOJ.1803.006.

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.